Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) shares traded up 0.6% on Thursday . The company traded as high as $1.82 and last traded at $1.82. 1,511 shares traded hands during mid-day trading, a decline of 6% from the average session volume of 1,601 shares. The stock had previously closed at $1.81.
Relief Therapeutics Price Performance
The stock’s 50 day moving average price is $2.99 and its 200-day moving average price is $3.25.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Read More
- Five stocks we like better than Relief Therapeutics
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- Executive Order 14330: Trump’s Biggest Yet
- The Crash Has Already Started (Most Just Don’t See It Yet)
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
